B
Beth E. Davis
Researcher at University of Saskatchewan
Publications - 100
Citations - 3075
Beth E. Davis is an academic researcher from University of Saskatchewan. The author has contributed to research in topics: Methacholine & Asthma. The author has an hindex of 22, co-authored 90 publications receiving 2809 citations.
Papers
More filters
Journal ArticleDOI
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gail M. Gauvreau,Paul M. O'Byrne,Louis-Philippe Boulet,Ying Wang,Donald W. Cockcroft,Jeannette Bigler,J. Mark FitzGerald,Michael Boedigheimer,Beth E. Davis,Clapton Dias,Kevin S. Gorski,Lynn Smith,Edgar Bautista,Michael R. Comeau,Richard Leigh,Jane R. Parnes +15 more
TL;DR: Findings are consistent with a key role for TSLP in allergen-induced airway responses and persistent airway inflammation in patients with allergic asthma and whether anti-TSLP therapeutics will have clinical value cannot be determined from these data.
Journal ArticleDOI
Mechanisms of airway hyperresponsiveness
TL;DR: One component of AHR is transient or inducible and occurs after allergen exposure, for example, and improves occasionally rapidly after inhaled corticosteroids or environmental control; however, this transient airway hyperresponsiveness is more marked to the indirect stimuli.
Journal ArticleDOI
Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma
Gail M. Gauvreau,Louis-Philippe Boulet,Donald W. Cockcroft,J. Mark FitzGerald,Christopher Carlsten,Beth E. Davis,Francine Deschesnes,MyLinh Duong,Billie Durn,Karen Howie,Linda Hui,Marion T. Kasaian,Kieran J. Killian,Tara X. Strinich,Richard M. Watson,Y. Nathalie,Simon Zhou,Donald G. Raible,Paul M. O'Byrne +18 more
TL;DR: IL-13 has a role in allergen-induced airway responses in humans and further study is required to determine whether anti- IL-13 monoclonal antibodies will be beneficial clinically.
Journal ArticleDOI
Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.
Gail M. Gauvreau,Louis-Philippe Boulet,Donald W. Cockcroft,Adrian J Baatjes,Johanne Côté,Francine Deschesnes,Beth E. Davis,Tara X. Strinich,Karen Howie,MyLinh Duong,Richard M. Watson,Paolo M. Renzi,Paul M. O'Byrne +12 more
TL;DR: TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma.
Journal ArticleDOI
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses
Gail M. Gauvreau,Jonathan P. Arm,Louis-Philippe Boulet,Richard Leigh,Donald W. Cockcroft,Beth E. Davis,Irvin Mayers,J. Mark FitzGerald,Barbro Dahlén,Kieran J. Killian,Michel Laviolette,Christopher Carlsten,Nikolaos Lazarinis,Richard M. Watson,Joanne Milot,Veronica A. Swystun,Miranda Bowen,Linda Hui,Ann-Sofie Lantz,Karin Meiser,Suzanne Maahs,Philip J. Lowe,Andrej Skerjanec,Anton Drollmann,Paul M. O'Byrne +24 more
TL;DR: QGE031 has greater efficacy than omalizumab on inhaled and skin allergen responses in patients with mild allergic asthma and these data support the clinical development of QGE031 as a treatment of asthma.